Advertisement mid banner S-Tech 1
Advertisement: Bar Ellison mid banner property
Advertisement: CJBS mid banner
Cambridgeand mid banner advertisement
Advertisement: Kao Data Centre mid banner
Advertisement: RSM mid banner
ARM Innovation Hub
Advertisement: partnersand mid banner
Advertisement: Excalibur Healthcare mid banner
Barr Ellison Solicitors – commercial property
Advertisement: HCR Hewitsons mid banner
Advertisement: Mogrify mid banner
Advertisement: Simpsons Creative
Advertisement: SATAVIA mid banner
Mid banner advertisement: BDO
Advertisement: EBCam mid banner
Advertisement: Cambridge Network mid banner
10 January, 2022 - 22:46 By Tony Quested

Illumina reveals genomics tech boom after smashing revenue records

Genomics sequencing powerhouse Illumina, whose European R & D hub is at Cambridge’s Granta Park, delivered a strong finish to 2021 with preliminary consolidated fourth quarter revenue of approximately $1.190 billion – up 25 per cent year-over-year. 

This record revenue for the quarter reflected new highs across both instruments and consumables. CEO Francis deSouza revealed.

Illumina also delivered preliminary fiscal year 2021 consolidated revenue of approximately $4.517bn – up 39 per cent on the previous year’s figures.
The returns reflected record revenue across all regions and the highest number of shipments in company history. 

The company expects another strong year in 2022 with consolidated revenue guidance of $5.15bn-$5.2-bn, or growth of 14-16 per cent as sequencing awareness, demand and adoption increase.

deSouza also announced new partnerships and technologies that will advance the company's mission of improving human health by unlocking the power of the genome.

He said: “We are seeing incredible acceleration of genomics in healthcare, driving an outstanding 2021 for Illumina and strong momentum for 2022 and beyond.

“With growth opportunities spanning our existing and evolving markets in both clinical and research genomics we are demonstrating through focused and continued innovation how unlocking the power of the genome improves human health. 

“Across all our markets, we are providing tools that enable today's researchers and clinicians to usher in the future of personalised medicine for patients around the world.”

Illumina is continuing its more than 20-year track record of innovation, and deSouza described the development of breakthrough chemistry, codenamed Chemistry X, that delivers two times faster cycle times, two times longer reads, and three times greater accuracy. 

This technology will generate cost efficiency on the path toward the $100 genome and lead to greater access, deeper sequencing and the next wave of discovery. deSouza indicated that breakthrough Chemistry X would serve as the foundation for all future platforms.

He further announced new patented technologies for a highly accurate and cost-effective long read workflow, codenamed Infinity, that will deliver contiguous data up to 10Kb in length to address the final edge cases of the genome. 

Infinity enables 10x greater throughput with 90 per cent less DNA input than legacy long reads, can be fully automated and is seamlessly compatible with sequencing by synthesis (SBS) chemistry – enabling it to be rapidly applied across Illumina's 20,000 instrument installed base.

Newsletter Subscription

Stay informed of the latest news and features